Yiduo Zhang

1.5k total citations
22 papers, 1.1k citations indexed

About

Yiduo Zhang is a scholar working on Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yiduo Zhang has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Public Health, Environmental and Occupational Health, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Yiduo Zhang's work include Obesity, Physical Activity, Diet (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). Yiduo Zhang is often cited by papers focused on Obesity, Physical Activity, Diet (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). Yiduo Zhang collaborates with scholars based in United States, Sweden and United Kingdom. Yiduo Zhang's co-authors include Timothy M. Dall, William W. Quick, Wenya Yang, Yaozhu J. Chen, Jeanene Fogli, Paul F. Hogan, Kristin J. Reimers, P. Packard, Victor L. Fulgoni and James D. Astwood and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and American Journal of Preventive Medicine.

In The Last Decade

Yiduo Zhang

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yiduo Zhang United States 15 275 197 164 155 146 22 1.1k
Sonja Lumme Finland 15 159 0.6× 111 0.6× 185 1.1× 215 1.4× 131 0.9× 37 1.2k
F Lucy Wright United Kingdom 11 109 0.4× 179 0.9× 145 0.9× 142 0.9× 179 1.2× 15 1.3k
Catherine Copley‐Merriman United States 22 376 1.4× 121 0.6× 202 1.2× 207 1.3× 256 1.8× 68 1.7k
Zahra Sohani Canada 16 372 1.4× 135 0.7× 128 0.8× 78 0.5× 135 0.9× 32 1.2k
Weiwei Gong China 18 215 0.8× 230 1.2× 145 0.9× 68 0.4× 169 1.2× 91 1.1k
Mark W. Donoghoe Australia 16 250 0.9× 113 0.6× 123 0.8× 97 0.6× 139 1.0× 53 1.1k
Spencer Phillips Hey United States 21 144 0.5× 268 1.4× 228 1.4× 213 1.4× 61 0.4× 68 1.5k
Wei‐Yen Lim Singapore 19 171 0.6× 99 0.5× 116 0.7× 125 0.8× 232 1.6× 44 1.1k
Wei Lin China 17 134 0.5× 265 1.3× 76 0.5× 176 1.1× 170 1.2× 107 1.0k
Tatiana Dilla Spain 20 598 2.2× 80 0.4× 76 0.5× 200 1.3× 188 1.3× 74 1.5k

Countries citing papers authored by Yiduo Zhang

Since Specialization
Citations

This map shows the geographic impact of Yiduo Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiduo Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiduo Zhang more than expected).

Fields of papers citing papers by Yiduo Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiduo Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiduo Zhang. The network helps show where Yiduo Zhang may publish in the future.

Co-authorship network of co-authors of Yiduo Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yiduo Zhang. A scholar is included among the top collaborators of Yiduo Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiduo Zhang. Yiduo Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koskimaki, Jacob E., Jenny Hu, Yiduo Zhang, et al.. (2022). Natural language processing-optimized case selection for real-world evidence studies.. Journal of Clinical Oncology. 40(16_suppl). 1556–1556. 2 indexed citations
2.
Garassino, Marina Chiara, Luis Paz‐Ares, Rina Hui, et al.. (2021). Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer. Future Oncology. 17(10). 1165–1184. 1 indexed citations
3.
Ouwens, Mario, Annie Darilay, Yiduo Zhang, et al.. (2021). Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research. 95. 100640–100640. 7 indexed citations
4.
5.
Mehra, Ranee, et al.. (2021). Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective. Journal of the National Comprehensive Cancer Network. 19(2). 153–162. 14 indexed citations
6.
7.
Ouwens, Mario, Pralay Mukhopadhyay, Yiduo Zhang, et al.. (2019). Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. PharmacoEconomics. 37(9). 1129–1138. 68 indexed citations
8.
Hui, Rina, Mustafa Özgüroğlu, Augusto Villegas, et al.. (2019). Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet Oncology. 20(12). 1670–1680. 115 indexed citations
9.
Larkindale, Jane, Wenya Yang, Paul F. Hogan, et al.. (2014). Cost of illness for neuromuscular diseases in the U.S. 1 indexed citations
10.
Larkindale, Jane, Wenya Yang, Paul F. Hogan, et al.. (2013). Cost of illness for neuromuscular diseases in the United States. Muscle & Nerve. 49(3). 431–438. 111 indexed citations
11.
Yang, Wenya, Timothy M. Dall, Yiduo Zhang, et al.. (2012). Simulation Of Quitting Smoking In The Military Shows Higher Lifetime Medical Spending More Than Offset By Productivity Gains. Health Affairs. 31(12). 2717–2726. 6 indexed citations
12.
Dall, Timothy M., Mary Roary, Wenya Yang, et al.. (2011). Health care use and costs for participants in a diabetes disease management program, United States, 2007-2008.. PubMed. 8(3). A53–A53. 18 indexed citations
13.
Dall, Timothy M., et al.. (2011). Weight Loss and Lifetime Medical Expenditures. American Journal of Preventive Medicine. 40(3). 338–344. 11 indexed citations
14.
Dall, Timothy M., Yiduo Zhang, Yaozhu J. Chen, et al.. (2010). The Economic Burden Of Diabetes. Health Affairs. 29(2). 297–303. 239 indexed citations
15.
Dall, Timothy M., Victor L. Fulgoni, Yiduo Zhang, et al.. (2009). Predicted National Productivity Implications of Calorie and Sodium Reductions in the American Diet. American Journal of Health Promotion. 23(6). 423–430. 25 indexed citations
16.
Harwood, Henrick J., et al.. (2009). Economic Implications of Reduced Binge Drinking Among the Military Health System’s TRICARE Prime Plan Beneficiaries. Military Medicine. 174(7). 728–736. 34 indexed citations
17.
Zhang, Yiduo, Timothy M. Dall, Wenya Yang, et al.. (2009). Medical Cost Associated with Prediabetes. Population Health Management. 12(3). 157–163. 45 indexed citations
18.
Fulgoni, Victor L., et al.. (2009). Potential Health Benefits and Medical Cost Savings from Calorie, Sodium, and Saturated Fat Reductions in the American Diet. American Journal of Health Promotion. 23(6). 412–422. 86 indexed citations
19.
Dall, Timothy M., Yiduo Zhang, William W. Quick, et al.. (2009). Distinguishing the Economic Costs Associated with Type 1 and Type 2 Diabetes. Population Health Management. 12(2). 103–110. 82 indexed citations
20.
Dall, Timothy M., et al.. (2007). Cost Associated with Being Overweight and with Obesity, High Alcohol Consumption, and Tobacco Use within the Military Health System's TRICARE Prime—Enrolled Population. American Journal of Health Promotion. 22(2). 120–139. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonja Lumme Breakdown of academic impact, for papers by F Lucy Wright Breakdown of academic impact, for papers by Catherine Copley‐Merriman Breakdown of academic impact, for papers by Zahra Sohani Breakdown of academic impact, for papers by Weiwei Gong Breakdown of academic impact, for papers by Mark W. Donoghoe Breakdown of academic impact, for papers by Spencer Phillips Hey Breakdown of academic impact, for papers by Wei‐Yen Lim Breakdown of academic impact, for papers by Wei Lin Breakdown of academic impact, for papers by Tatiana Dilla
Rankless by CCL
2026